[go: up one dir, main page]

CA2732863A1 - Composition pharmaceutique pour prevenir ou traiter l'osteoporose a base de derives de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci - Google Patents

Composition pharmaceutique pour prevenir ou traiter l'osteoporose a base de derives de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci Download PDF

Info

Publication number
CA2732863A1
CA2732863A1 CA2732863A CA2732863A CA2732863A1 CA 2732863 A1 CA2732863 A1 CA 2732863A1 CA 2732863 A CA2732863 A CA 2732863A CA 2732863 A CA2732863 A CA 2732863A CA 2732863 A1 CA2732863 A1 CA 2732863A1
Authority
CA
Canada
Prior art keywords
thiazol
isopropyl
methyl
pentoxy
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2732863A
Other languages
English (en)
Inventor
Jin Soo Lee
Yun Ha Hwang
Jei Man Ryu
Jae Hoon Park
Duk Kyun Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong Wha Pharm Co Ltd
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of CA2732863A1 publication Critical patent/CA2732863A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2732863A 2008-08-01 2009-07-31 Composition pharmaceutique pour prevenir ou traiter l'osteoporose a base de derives de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci Abandoned CA2732863A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2008-0075792 2008-08-01
KR20080075792 2008-08-01
PCT/KR2009/004277 WO2010013969A2 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci

Publications (1)

Publication Number Publication Date
CA2732863A1 true CA2732863A1 (fr) 2010-02-04

Family

ID=41610865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2732863A Abandoned CA2732863A1 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prevenir ou traiter l'osteoporose a base de derives de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci

Country Status (6)

Country Link
EP (1) EP2307015A4 (fr)
JP (1) JP2011529875A (fr)
KR (1) KR20100014173A (fr)
CN (1) CN102149380B (fr)
CA (1) CA2732863A1 (fr)
WO (1) WO2010013969A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
CN1144806A (zh) * 1996-07-25 1997-03-12 南京药物研究所 氨基二膦酸类骨吸收抑制剂及其钠盐的制备方法
KR100513302B1 (ko) * 1997-02-04 2005-11-11 동화약품공업주식회사 3-아미노-1,2-벤조이소옥사졸 유도체, 이의 제조방법및 용도
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
JP2003292453A (ja) * 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
EP1640010A1 (fr) * 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent d'induction de croissance dans la masse osseuse
KR20060056377A (ko) * 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
EP1742631A4 (fr) * 2004-04-28 2009-11-11 Merck & Co Inc 4-azasteroides fluores utilises en tant que modulateurs du recepteur androgene
ES2359721T3 (es) * 2004-07-05 2011-05-26 Dong Wha Pharmaceutical Co., Ltd. Composición farmacéutica para el tratamiento de fracturas óseas.
JP2009017222A (ja) * 2007-07-04 2009-01-22 Panasonic Corp 色調整装置、色調整方法および色調整装置の集積回路
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
WO2010013969A2 (fr) 2010-02-04
JP2011529875A (ja) 2011-12-15
EP2307015A2 (fr) 2011-04-13
CN102149380A (zh) 2011-08-10
CN102149380B (zh) 2012-12-05
EP2307015A4 (fr) 2012-05-16
WO2010013969A3 (fr) 2010-05-27
KR20100014173A (ko) 2010-02-10

Similar Documents

Publication Publication Date Title
US8119649B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
US8008329B2 (en) Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate
KR20130128451A (ko) 지방이상증의 치료
KR100454767B1 (ko) 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
CA2732864A1 (fr) Composition pharmaceutique pour prevenir ou traiter l'osteoporose comprenant un derive de benzamidine ou un sel de celui-ci, et du bisphosphonate
US20150005506A1 (en) Therapeutic agent for diabetes
JP2019530743A (ja) 筋萎縮の治療におけるトリプトファン代謝物質の使用
US7964584B2 (en) Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
KR20170137201A (ko) 근육 위축 치료에 사용되는 유도체
CA2732863A1 (fr) Composition pharmaceutique pour prevenir ou traiter l'osteoporose a base de derives de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci
KR20200016640A (ko) 금제제를 유효성분으로 포함하는 파골세포 분화 억제용 조성물
US12383511B2 (en) Osteogenic agents and uses thereof
US20230390262A1 (en) Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for treating sarcopenia and frailty
KR20100017460A (ko) 피피에이알 감마 작용물질로 인한 부작용의 예방에 유용한 조성물
EP2177219A1 (fr) Agent préventif ou agent thérapeutique pour une maladie provoquée par un métabolisme osseux anormal
NZ535081A (en) Combinations comprising epothilone derivatives and alkylating agents
CA3205111A1 (fr) Schemas posologiques pour inhibiteurs oraux de la kinase alk2
JPH11116501A (ja) 骨吸収関連疾患治療剤
HK1143329A (en) Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism
HK1164170A (en) Prophylactic or therapeutic agent for diseases associated with abnormal bone metabolism

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140731